Theralase concludes $1.17M private placement for cancer treatment advancements

Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) has completed a non-brokered private placement, issuing 5,318,183 units at $0.22 per unit, yielding approximately $1,170,000. Each unit includes a common share and a common share purchase warrant, allowing warrant holders to acquire an additional common share at $0.28 within 5 years. The funds raised will support the ongoing Phase II clinical study for Non-Muscle Invasive Bladder Cancer and address working capital requirements in Theralase's pursuit of innovative cancer, bacteria, and virus treatment developments.